Joana Xará

Joana Xará

Auto-generated profile, based on publicly available information

Joana Xará

Department of Dermatology and Venereology, University Hospital Local Health Unit of Coimbra Coimbra Portugal

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in International Journal of Dermatology
Verified
Journal Article
Closed access
JXJoana Xará
Joana Xará
PFPedro Farinha
Pedro Farinha
ALAna M. Lé
Ana M. Lé
BDBruno Duarte
Bruno Duarte
TTTiago Torres
Tiago Torres
MGMargarida Gonçalo
Margarida Gonçalo

27 March 2023 in Contact Dermatitis
Verified
Journal Article
Closed access
JXJ. Xará
J. Xará
AMA. Matos
A. Matos
JSJ. Soares
J. Soares
JTJ. Teixeira
J. Teixeira
LRL. Ramos
L. Ramos
MGM. Gonçalo
M. Gonçalo

18 June 2024 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
APAndré Pinho
André Pinho
ABAna Brinca
Ana Brinca
JXJoana Xará
Joana Xará
MBMariana Batista
Mariana Batista
RVRicardo Vieira
Ricardo Vieira

5 November 2024 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
JXJoana Xará
Joana Xará
JTJoão Teixeira
João Teixeira
MBMaria Manuel Brites
Maria Manuel Brites
JCJosé Carlos Cardoso
José Carlos Cardoso

21 November 2024 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
JTJoão Pedro de Jesus Teixeira
João Pedro de Jesus Teixeira
DFDuarte Flor
Duarte Flor
JXJoana Xará
Joana Xará
MGMargarida Gonçalo
Margarida Gonçalo
Type I hereditary angio-oedema (HAE) is a rare autosomal dominant disorder characterized by recurrent bradykinin-mediated angio-oedema affecting the skin, respiratory system and gastrointestinal tract. Lanadelumab, a monoclonal antibody targeting plasma kallikrein to reduce bradykinin production, has shown efficacy in long-term prophylaxis (LTP) for patients aged 2 years and above, with a recommended dose of 300 mg biweekly. We present two cases of patients with type I HAE, poorly controlled with traditional LTP therapies, demonstrating complete response and extended attack-free intervals with lanadelumab, suggesting that administration intervals beyond 4 weeks may be feasible, improving patient quality of life and healthcare cost-effectiveness.

4 June 2025 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
DCDavid G Caetano
David G Caetano
MPMariana Pedroso
Mariana Pedroso
DFDuarte Flor
Duarte Flor
JXJoana Xará
Joana Xará
JCJosé Carlos Cardoso
José Carlos Cardoso
MBMaria Manuel Brites
Maria Manuel Brites
This case report presents a healthy woman with ulcerative cribriform ulcers in the frontal area that were diagnosed as superficial granulomatous pyoderma. This disorder is an uncommon variant of pyoderma gangrenosum, which is more chronic and painless, with a particular lack of association with systemic illnesses. Exclusive facial involvement is exceedingly rare in this entity.